April 2023 Issue Table Of Contents

From The Editor

• The Growing Appetite For Obesity Drugs

Feature Articles

• U.S. Patent Expired? Why Not Grow Revenue Globally, Says Amarin
• Hitting The Ground Running In Oncology

CEO Corner

• Making The Jump From Big Pharma To Biotech

Companies To Watch

• KaliVir Immunotherapeutics

Industry Research

• Decentralized Clinical Trial Predicted Use

Podcast Summary

• Tech-Heavy Drug Discovery Yields Deep Pipeline

Industry Leader

• Human Analysis Still Imperative When Using AI For Data Management
• Explaining Private Equity’s Increased Appetite For Drug Development
• Today’s Life Science Recruitment Challenges

Inside The Industry

• COVID Continues To Impact Outsourced Manufacturing And Supply Chain Security
• Avoid Launch Delays By Planning For An FDA-Required REMS
• New EU Directive Marks Cybersecurity Regulatory Paradigm Shift
• How Biopharmas Can Navigate Data Privacy Laws And Unlock Value
• Sites Look To Unravel The Tech Tangle Of Decentralization
• GMP Principles: The True Star Of Cell & Gene FDA Interactions
• The FDA’s Final Guidance On Early-Phase Cell & Gene Therapy Trials
• Promoting Inclusion In Clinical Trials: Changing Perceptions And Disparities
• Vor Bio’s Transition Into Clinical Trials

Leadership Lessons

• What It Means To Put People First In Leadership

Ask The Board

• What Is The Role Of Generative AI In The Life Sciences Industry?
• How Will Industry Work With Congress To Make The Inflation Reduction Act (IRA) Workable?